Bimekizumab

1 Drug classified under this active ingredient

Human Monoclonal Antibody. Bimekizumab 160 mg/ml.
Pre-filled pen sol. for SC inj. 160 mg/ml
 320 mg (given as 2 inject. of 160 mg each) at week 0, 4, 8, 12, 16 and every 8 weeks after.
 Tmt. of mod. to sev. plaque psoriasis in adlts. candidates for syst. ther.
C/I:Hypersens. Clinic. import. active infect.(e.g. act. TB)